French Biotech ExonHit to Acquire RedPath for $32M to Boost US Presence

ExonHit CEO Loic Maurel said that the transaction, scheduled to close in July, is a "significant milestone in ExonHit's strategy to become an internationally recognized player in molecular diagnostics," and will "strengthen" the firm's presence in the US.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.